Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

ARTICLES

Close-up on traditional lab biomarkers for MS

February 2026—The 2024 revision of the 2017 McDonald criteria for diagnosing multiple sclerosis allows the kappa-free light chain index to replace oligoclonal band detection in cerebrospinal fluid analysis.

Pathologists, vendors talk LIS-IMS integration

February 2026—Cybersecurity and image management are key concerns for laboratories adopting digital pathology and AI. While cloud-based systems offer enhanced security and scalability, onboarding new vendors and instruments remains challenging due to stringent security requirements and potential vulnerabilities.

Developing novel assays for disease states

February 2026—This is the fourth in a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with representatives of a company to spotlight its laboratory solutions. He spoke on Dec. 2, 2025 with Steve Swartzell and Scott Johnston of ELITechGroup.

Traumatic brain injury biomarkers, one year in

January 2026—Michigan Medicine implemented two biomarkers, GFAP and UCH-L1, to evaluate traumatic brain injury in the emergency department, aiming to reduce unnecessary CT scans. A retrospective study showed high sensitivity for the markers, but limitations were identified, such as their ineffectiveness for …

AI ‘bottleneck’: putting the algorithms to work

January 2026—Despite significant advancements in algorithm development, implementing AI in clinical practice faces a bottleneck. The challenge lies in operationalizing these algorithms within existing clinical workflows, requiring infrastructure, reimbursement structures, and validation frameworks.